CytoAgents is a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system causing systemic inflammation. There are many causes of CRS and our mission is to develop a broadly accessible treatment for multiple indications of high unmet need.
Using a novel approach by calming the natural immune response to a multi organ disease, CytoAgemts' lead drug candidate, GP1681, is positioned to become a new best practice in medicine.
Company Details
- Employees
- 10
- Founded
- -
- Address
- Alloy 26, 100 S. Commons,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- cytoagents.com
- Keywords
- Biotechnology, Immunotherapy, Infectious, Drug Development, Pharmaceutics, Influenza, Medical Technology, Patient Safety, Medical Cost Containment, Public Health, Healthcare Management, Life Sciences, COVID19, Coronavirus, Cytokine, Virology.
- HQ
- Pittsburgh, Pennsylvania
Cytoagents, Inc Questions
Cytoagents, Inc's website is cytoagents.com
Cytoagents, Inc's LinkedIn profile is https://www.linkedin.com/company/cytoagents
Cytoagents, Inc has
10 employees.
View email and phone details for 10
employees at Cytoagents, Inc.
Cytoagents, Inc's industry is
Biotechnology Research
Cytoagents, Inc's top competitors are
Bluesphere Bio,
Cognition Therapeutics, Inc.,
Behaivior,
Imagine Pharma,
Ariel Precision Medicine,
Noveome Biotherapeutics, Inc.,
Avista Therapeutics,
Myris Therapeutics,
Carmell Cosmetics,
Peptilogics.
Cytoagents, Inc's categories are Biotechnology Research
Cytoagents, Inc's founding year is 2018
